Close

Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)

Industry Reports
Typography

Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.

Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD).

Results from the study will be presented during the Plenary Scientific Session at the 58thAmerican Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, California."Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease," said Bruno Strigini, CEO of Novartis Oncology. "With this acquisition, Novartis is able to leverage its leadership in hematology research to advance development of a potential new treatment option for patients living with this debilitating condition."

SCD is a hereditary blood disorder characterized by sickle-shaped red blood cells[1]. It is a life-long disease with many forms that can range in clinical severity from asymptomatic to life-threatening.[1] Vaso-occlusive crises, or pain crises, are the major reason for health care encounters in SCD and occur episodically when sickle-shaped red blood cells block blood flow through blood vessels.[2],[3]"We would like to extend our gratitude to all of the dedicated patients, physicians and nurses who participated in the SUSTAIN study of SelG1 in sickle cell disease," said Dr. Scott Rollins, former President and Chief Executive Officer of Selexys Pharmaceuticals. "Further, the acquisition of Selexys by Novartis represents an important step in the continued development of SelG1, a novel, potential first-in-class therapy for patients with this underserved life-threatening disease."Novartis obtained the exclusive right to acquire Selexys and SelG1 in 2012. Prior to the acquisition, Selexys Pharmaceutical Corporation was a privately held biopharmaceutical company headquartered in Oklahoma City, Oklahoma. Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments.

About Novartis:
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com

References

[1] National Heart, Lunch and Blood Institute. What Is Sickle Cell Disease? Last updated: August 2, 2016. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/sca (link is external). Accessed on October 13, 2016. 

[2] Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood. 2008;111(3):997-1003. Published online October 16, 2007. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17940207 (link is external). Accessed October 13, 2016.

[3] The Mayo Clinic. Diseases and Conditions: Sickle Cell Anemia. Mayo Clinic Staff. Last updated June 2014. Available from http://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/basics/symptoms/con-20019348 (link is external). Accessed October 13, 2016.

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail:This email address is being protected from spambots. You need JavaScript enabled to view it.

Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
This email address is being protected from spambots. You need JavaScript enabled to view it.

Jeannie Neufeld
Novartis Oncology Communications
+1 862 778 2104 (direct)
+1 201 650 2728 (mobile)
This email address is being protected from spambots. You need JavaScript enabled to view it.

Novartis Investor Relations
Central investor relations line:
+41 61 324 7944
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok